Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal

Heather JonesDepartment of Pathology, University of TX Southwestern Medical Center, Dallas, TX, USA

https://orcid.org/0000-0003-4491-4587 View further author information

Nicole De SimoneDepartment of Pathology, University of TX Southwestern Medical Center, Dallas, TX, USAView further author information

Christopher WebbDepartment of Pathology, University of TX Southwestern Medical Center, Dallas, TX, USACorrespondence[email protected]
View further author information

References

Niessner A, Tamargo J, Morais J, et al. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on cardiovascular pharmacotherapy and European Society of Cardiology Working Group on thrombosis. Eur Heart J. 2017;38(22):1710–1716. doi: 10.1093/eurheartj/ehv676.
PubMed Web of Science ®Google Scholar
Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. J Am Coll Cardiol. 2020;76(5):594–622. doi: 10.1016/j.jacc.2020.04.053.
PubMed Web of Science ®Google Scholar
Giannandrea D, Mengoni A, Carluccio E, et al. Practical considerations on anticoagulation reversal: spotlight on the reversal of dabigatran. Vasc Health Risk Manag. 2019;15:139–142. doi: 10.2147/VHRM.S181806.
PubMed Web of Science ®Google Scholar
Yee J, Kaide CG. Emergency reversal of anticoagulation. West J Emerg Med. 2019;20(5):770–783. doi: 10.5811/westjem.2018.5.38235.
PubMed Web of Science ®Google Scholar
Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017;377(5):431–441. doi: 10.1056/NEJMoa1707278.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Laboratory-guided repeat dosing of idarucizumab for dabigatran reversal

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date